PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.83%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.83%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-17.79%
Negative net income growth while TRVN stands at 0.97%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-12.12%
Negative EPS growth while TRVN is at 3.98%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-9.09%
Negative diluted EPS growth while TRVN is at 3.98%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
5.06%
Share count expansion well above TRVN's 3.14%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.04%
Diluted share count expanding well above TRVN's 3.14%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Negative OCF growth while TRVN is at 11.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-120.93%
Negative FCF growth while TRVN is at 11.01%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Negative 10Y OCF/share CAGR while TRVN stands at 75.54%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.56%
5Y OCF/share CAGR 1.25-1.5x TRVN's 68.08%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
77.71%
3Y OCF/share CAGR above 1.5x TRVN's 6.66%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
99.67%
Net income/share CAGR 1.25-1.5x TRVN's 70.67%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
85.97%
5Y net income/share CAGR 1.25-1.5x TRVN's 67.35%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
69.72%
3Y net income/share CAGR above 1.5x TRVN's 6.10%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
173.45%
Equity/share CAGR of 173.45% while TRVN is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-62.01%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
56.61%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-13.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.77%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
45.24%
R&D growth drastically higher vs. TRVN's 22.72%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-4.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.